Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Alpine Immune Sciences Inc (ALPN)
Alpine Immune Sciences Inc (ALPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 474,863
  • Shares Outstanding, K 47,966
  • Annual Sales, $ 30,060 K
  • Annual Income, $ -57,760 K
  • 60-Month Beta 1.26
  • Price/Sales 16.03
  • Price/Cash Flow N/A
  • Price/Book 2.84
Trade ALPN with:

Options Overview Details

View History
  • Implied Volatility 130.26% ( +42.12%)
  • Historical Volatility 60.13%
  • IV Percentile 84%
  • IV Rank 72.48%
  • IV High 179.65% on 01/04/23
  • IV Low 0.18% on 08/31/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 10
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 104
  • Open Int (30-Day) 144

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.38
  • Number of Estimates 6
  • High Estimate -0.30
  • Low Estimate -0.50
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +36.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.71 +47.54%
on 05/04/23
10.95 -9.59%
on 05/23/23
+2.69 (+37.31%)
since 04/26/23
3-Month
6.39 +54.81%
on 03/27/23
10.95 -9.59%
on 05/23/23
+2.29 (+30.09%)
since 02/24/23
52-Week
4.82 +105.39%
on 10/24/22
10.95 -9.59%
on 05/23/23
+0.89 (+9.88%)
since 05/26/22

Most Recent Stories

More News
Neurocrine Biosciences (NBIX) Reports Q1 Loss, Tops Revenue Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -403.85% and 1.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

NBIX : 91.22 (-1.04%)
ALPN : 9.90 (-1.49%)
Alpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare Conference

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the...

ALPN : 9.90 (-1.49%)
Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Lags Revenue Estimates

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -51.85% and 73.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

ALPN : 9.90 (-1.49%)
BVS : 2.86 (+8.75%)
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate...

ALPN : 9.90 (-1.49%)
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present posters at...

ALPN : 9.90 (-1.49%)
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present an ePoster...

ALPN : 9.90 (-1.49%)
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company...

ALPN : 9.90 (-1.49%)
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will participate in two...

ALPN : 9.90 (-1.49%)
Alpine Immune Sciences to Participate in the SVB Securities Global Biopharma Conference

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company...

ALPN : 9.90 (-1.49%)
Are Options Traders Betting on a Big Move in Alpine (ALPN) Stock?

Investors need to pay close attention to Alpine (ALPN) stock based on the movements in the options market lately.

ALPN : 9.90 (-1.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based...

See More

Key Turning Points

3rd Resistance Point 10.50
2nd Resistance Point 10.35
1st Resistance Point 10.13
Last Price 9.90
1st Support Level 9.76
2nd Support Level 9.61
3rd Support Level 9.39

See More

52-Week High 10.95
Last Price 9.90
Fibonacci 61.8% 8.61
Fibonacci 50% 7.89
Fibonacci 38.2% 7.16
52-Week Low 4.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar